Open AccessWhen to Initiate Disease-Modifying Drugs for Relapsing Remitting Multiple Sclerosis in Adults?
Author(s) -
Mona Alkhawajah,
Joël Oger
Publication year - 2011
Publication title -
multiple sclerosis international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
H-Index - 6
eISSN - 2090-2662
pISSN - 2090-2654
DOI - 10.1155/2011/724871
Subject(s) - glatiramer acetate , relapsing remitting , multiple sclerosis , medicine , disease , intensive care medicine , immunology
For patients with Relapsing Remitting Multiple Scierosis Beta Interfaerons and Glatiramer Acetate were the first to be licensed for treatment. This review deals with one major question: when to initiate therapy? Through exploring the unique characteristics of the disease and treatement we suggest an approach that should be helpful in the process of decision-making.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom